Shares of Adma Biologics (ADMA) have gained 18.9% over the past four weeks to close the last trading session at $5.23, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $6.88 indicates a potential upside of 31.6%.The average comprises four short-term price targets ranging from a low of $6 to a high of $9, with a standard deviation of $1.44. While the lowest estimate indicates an i ...